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INTRODUCTION
Breast augmentation is one of the most popular pro-
cedures in plastic surgery worldwide. In 2017, 333.392 
patients underwent breast augmentation, thus, making 
it the most commonly performed surgical procedure in 
the United States.1 A particularly devastating postopera-
tive complication is surgical-site infection (SSI), occurring 
in 2%–2.5% of patients following breast augmentation.2 
Importantly, one has to distinguish between early and 
late infection, the latter believed to be associated with the 
development of capsular contracture.3–7
Acute infections occur between the first and the sixth 
week postoperatively. Clinical signs include erythema, 
edema, and pain, in addition to changes in labora-
tory parameters, including leukocytosis and elevated 
c-reactive protein and procalcitonin. In contrast, late 
infections manifest months to years after implant place-
ment and are often subclinical.8 In light of the devas-
tating consequences of SSI, the issue of prophylactic 
antibiotic administration deserves special attention. 
The importance of this topic, however, is contrasted by 
the lack of widely accepted evidence-based guidelines 
addressing the issue of perioperative antibiotic prophy-
laxis. An unsolved problem remains prevention of capsu-
lar contracture. A variety of theories have been proposed 
related to its underlying pathomechanism, including 
immunologic factors and biofilm formation.4,9 Given 
these theories, prophylactic antibiotic administration, 
in addition to surgical technique (Bill Adams paper-14-
point plan), appears to be a critical intervention.6 It is, 
therefore, not surprising that an increase in the use of 
antibiotics has been noted over time.10 Yet, it is important 
to acknowledge that antibiotics can have serious adverse 
drug events, including allergic reactions, bacterial resis-
tance, and clostridium difficile infection.11 Furthermore, 
it is unclear if antibiotics can effectively prevent biofilm 
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After postmastectomy reconstruction (secondary reconstruction), the rates are 
even higher. The microorganisms seen in acute infections are Gram-positive, 
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negative and from normal skin flora with low virulence. In primary implantation, 
a weight-based dosing of cefazolin is adequate, an extra duration of antibiotic 
cover does not provide further reduction in superficial or periprosthetic infec-
tions. Clindamycin and vancomycin are recommended alternative for patients 
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varies (Gram-positive and Gram-negative), and the antibiotic prophylaxis (fluo-
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Several studies have demonstrated that bacterial con-
tamination is present in up to 66% of patients with high-
grade capsular contracture.13 In fact, studies of patients 
with breast implants have demonstrated that many 
implant pockets contain Gram-positive bacteria with the 
predominant species being local skin flora (coagulase-
negative staphylococci [CNS], Propionibacterium acnes, 
Corynebacterium species). In light of this bacterial spec-
trum, the use of prophylactic cefazolin seems justified.14 
Recent studies hypothesize a discrepancy between antibi-
otic activity of commonly used antibiotics for preoperative 
prophylaxis of SSIs in patients with implant replacement 
and microorganisms found by sonication on breast 
implants, suspected to trigger the formation of capsular 
contracture.15
In several studies, an ultrasound bath of the explanted 
breast implants to create a fluid targeted with microor-
ganisms was used (sonication).16 A significant correlation 
between degree of capsular contracture and culture posi-
tivity after sonication17 was targeted. The main group of 
bacteria found was Propionibacterium species and CNS18,19 
(Fig. 1).
Prophylaxis
Preoperative antibiotics are used to prevent postop-
erative infections, including SSI20 and bacteremia-induced 
joint prosthesis infection or infective endocarditis in high-
risk patients.21
Breast augmentation is considered a clean procedure. 
However, breast tissue contains bacteria, thus, presenting 
a risk for implant contamination and postoperative infec-
tion.22 Preoperative risk factors for developing a SSI after 
breast surgery include advanced age, poor nutritional 
status, obesity, diabetes mellitus, smoking, presence of 
infection, immunodeficiency or immunosuppressive use, 
steroid use, recent surgery, long preoperative hospitaliza-
tion, and colonization with microorganisms.4,23 In addition 
to patient factors, surgical technique can impact infec-
tion rates, as demonstrated by a higher number of SSIs 
associated with periareolar or transareolar approaches.24 
Glove changes are recommended before treating the 
implants as well as the use of devices that minimize skin con-
tact during implant insertion (“no touch technique”).17,25 
Finally, the plane of implant insertion (subglandular ver-
sus subpectoral) and their surface characteristics (smooth 
versus textured) affect infection rates.26,27
Ariyan et al presented the results of an evidence-based 
consensus conference on antibiotic prophylaxis for pre-
venting SSI in plastic surgery.28 They concluded that anti-
biotic prophylaxis (versus control) was associated with a 
significant risk reduction of SSI (2.5% versus 11.4%; odds 
ratio, 0.16; 95% CI, 0.04–0.61; P = 0.01) for patients follow-
ing breast augmentation.28 These findings were, however, 
not replicated by Hardwicke et al who did not identify a 
beneficial effect of antibiotics on infection rates following 
breast augmentation.29 Given these contradicting reports, 
a widely accepted consensus on antibiotic prophylaxis 
in augmentation mammaplasty is still lacking.30 A rea-
sonable approach might be to administer antimicrobial 
prophylaxis in clean wounds that are at risk of wound 
infection due to patient comorbidities or prolonged pro-
cedure length, complicated anatomy, choice of surgical 
technique/approach,31 and clean-contaminated wounds 
(implant-based breast cancer reconstruction).32 There 
is no evidence that prolonged postoperative antibiotic 
administration in primary or secondary cosmetic breast 
augmentation reduces postoperative complication rate, 
infection, or capsular contracture.33,34
Choice of Antibiotics
Most surgeons prefer a first-generation cephalospo-
rine for antibiotic prophylaxis.35 The Sanford guide to 
antimicrobial therapy recommends cefazolin 1–2 mg 
intravenous single shot preoperatively for breast sur-
gery.36 Early/acute infections occur within the first 
6 weeks after surgery and are mainly caused by Gram-
positive microorganisms of endogenous breast flora, 
such as Staphylococcus aureus, methicillin-resistant 
Fig. 1. Differences between acute and late infections.
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S. aureus, Streptococcus pyogenes, P. acnes, Diphtheroids, 
Lactobacilli, or Bacillus species.36,37 Clinical studies on cap-
sular contracture as a common endpoint of late infec-
tion have identified a different bacterial spectrum, that 
is, Propionibacterium avidum and CNS.38,39 These species 
are not particularly susceptible to the commonly used 
cephalosporin. Hence, glycopeptides (vancomycin) have 
been proposed for the purpose of reducing the risk of 
capsular contracture because they are highly effective 
against Gram-positive organisms like Propionibacterium 
species and CNS.40,41 In concordance with this hypothe-
sis, Chidester et al14 challenge the default use of cefazolin 
in a single-center study with 553 patients showing a rela-
tively high resistance to cefazolin and clindamycin but 
vancomycin covering 100% of Gram-positive organisms.
For primary augmentation, cefazolin is most com-
monly recommended and is congruent with a recent 
report of 97% of plastic surgeons using this regimen.35 In 
secondary implant breast reconstruction and when replac-
ing implants, the use of fluoroquinolones  and vancomy-
cin is necessary due to extended microbiologic spectrum 
with Gram-positive and Gram-negative microorganism. 
When changing implants, it is recommended to obtain 
specimen for microbiologic examination. In addition to 
histologic examination of the capsule, seroma fluid (when 
present) should be examined for CD30 and anaplastic 
lymphoma kinase to exclude anaplastic large cell lym-
phoma (Fig. 2).42,43
Duration and Timing of Antibiotic Prophylaxis
A single dose of intravenous antibiotic is adequate for 
prophylaxis in primary breast augmentation surgery and 
minimizes the risks associated with prolonged antibiotic use.44 
This is particularly important as prolonged antibiotic admin-
istration does not reduce postoperative infection rates.45
The first dose of antimicrobial should be adminis-
tered 60 minutes before skin incision. Vancomycin and 
fluoroquinolones should be administered within 120 min-
utes before skin incision due to the prolonged infusion 
times required for these drugs. The longer half-lives of 
these antibiotics guarantee high serum levels during most 
surgical procedures.46
In primary and secondary breast reconstruction, a peri-
operative single dose of intravenous antibiotic is enough. 
The timing should be 60 minutes before surgical incision 
for cephalosporins. If additional antibiotics are necessary 
(vancomycin/flourchinolone), administration should be 
done 120 minutes before incision.
CONCLUSIONS
In primary augmentation, a single dose of intravenous 
weight-based cefazolin before skin incision appears to be 
adequate. Clindamycin or vancomycin is recommended 
for patients with β-lactam allergies. In secondary breast 
surgery, that is, implant replacement, antibiotic cover-
age should be broadened to include flourchinolones and 
vancomycin.
Using the principles of the 14-point-plan by Adams et 
al6 to minimize the bacterial load at the time of surgery, 
the development of subclinical infection and capsulare 
contracture may be reduced.
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